HCC and Tumor Biomarkers: Does One Size Fits All?

Hepatocellular carcinoma (HCC) is a highly malignant disease and early diagnosis rates remain to be unsatisfactory. Owing to this limitation, advances in treatment options including liver transplantation (LT) are limited to improve survival. Recent HCC guidelines no longer recommend alpha-fetoprotei...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of gastrointestinal cancer Vol. 51; no. 4; pp. 1122 - 1126
Main Authors:	Ozgor, Dincer, Otan, Emrah
Format:	Journal Article
Language:	English
Published:	New York Springer US 01-12-2020
Subjects:	Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Cancer Research Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - therapy Early Detection of Cancer - methods Gastroenterology Humans Internal Medicine Liquid Biopsy - methods Liver - pathology Liver Neoplasms - blood Liver Neoplasms - diagnosis Liver Neoplasms - genetics Liver Neoplasms - therapy Medicine Medicine & Public Health Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - prevention & control Neoplasm Staging - methods Oncology Radiotherapy Review Article Risk Assessment - methods Sensitivity and Specificity Treatment Outcome Biomarkers Hepatocellular carcinoma Alpha-fetoprotein
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!